Merck & Co., Inc. Release: Results Of Phase II Study Shows MK-0518, Provides Superior Reduction In HIV Viral RNA Vs. Placebo In Treatment-Naive HIV-Infected Patients
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 18, 2005--Merck & Co., Inc. In a 10-day monotherapy trial, patients taking MK-0518 achieved a 98 percent reduction in HIV-RNA across all dosages tested, and at least half achieved HIV-RNA copies of 400 per mL or less.